CALCA and migraine disorder: Monoclonal antibodies (mAbs) against CGRP or its receptor, including erenumab, fremanezumab, galcanezumab, and eptinezumab, have shown promising efficacy in reducing migraine frequency and improving quality of life with favorable tolerability profiles [5].